Santhera Proposes Srishti Gupta Director
Analysis based on 8 articles · First reported Apr 30, 2026 · Last updated Apr 30, 2026
The proposed election of Dr. Srishti Gupta to the board of Santhera Pharmaceuticals is expected to positively impact the company's market sentiment due to her strong track record in biopharmaceuticals and value creation. Her expertise is anticipated to support Santhera Pharmaceuticals' next phase of growth and global expansion of AGAMREE, potentially leading to increased investor confidence.
Santhera Pharmaceuticals has proposed the election of Dr. Srishti Gupta as an Independent Director at its upcoming Annual General Meeting on May 26, 2026. Dr. Srishti Gupta is a physician executive with over 20 years of leadership experience in biopharmaceuticals, global health, and strategy consulting. She previously served as CEO of Idorsia Ltd, where she successfully led a turnaround, significantly increasing revenues and market capitalization. Her extensive background, including 18 years at McKinsey & Company, is expected to be invaluable to Santhera Pharmaceuticals as it aims to expand global access to its product AGAMREE and enter a new phase of growth.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard